- Home
- RDCM vs IKT Comparison
RDCM vs IKT Comparison
Compare RDCM & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | IKT |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.7M | 201.3M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RDCM | IKT |
|---|---|---|
| Price | $11.60 | $1.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $6.00 |
| AVG Volume (30 Days) | 94.4K | ★ 2.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.88 | $1.33 |
| 52 Week High | $15.14 | $2.58 |
Technical Indicators
Market Signals| Indicator | RDCM | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 58.56 |
| Support Level | $10.77 | $1.45 |
| Resistance Level | $13.65 | $2.11 |
| Average True Range (ATR) | 0.70 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 34.60 | 55.80 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.